Skip to content
MarketScale
‹ Back to IndustriesSciences

The Space Race Is Back and Heading to the Public Market

The return of the space race has more companies and investors looking for ways to get into the industry. Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019. The California garage startup, which now occupies a quarter-of-a-million square foot facility…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · AstraBloombergOuter SpacePublic
Share
The Space Race Is Back and Heading to the Public Market

Key takeaways

01

The return of the space race has more companies and investors looking for ways to get into the industry.

02

Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019.

03

The California garage startup, which now occupies a quarter-of-a-million square foot facility…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

The return of the space race has more companies and investors looking for ways to get into the industry. Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019. The California garage startup, which now occupies a quarter-of-a-million square foot facility in Alameda, is valued at $2 Billion. The company provides rocket launches for $3 Million each, significantly less than that of SpaceX and Rocket Lab. Watch Emily Chang’s report above or read the transcript below.

From home garage to full fledged rocket company, Astra is the latest upstart looking to make its name in the space race with big ambitions to ramp up to a rocket launch a day delivering things like satellites, supplies and other cutting edge technology to space within the next four years. To raise capital and fast CEO Chris Kemp plans to capitalize on the SPAC craze, and take the company public this year in a merger with Holicity, run by Billionaire and former telecom mogul Craig McCaw.

Astra would be the latest space back since virgin galactic, which merged with social capital in 2019. Astra, though, wasn’t founded by a billionaire. It started operations in a San Francisco garage with limited funding. The company now designs tests and manufactures a line of small, relatively cheap rockets at its current factory just over the Bay Bridge in Alameda, California. A former Naval base, now home to served as a jet engine research facility and gained popularity as the site of Discovery Channel’s Mythbusters.

The team occupies a quarter of a million square foot research facility where researchers, engineers and scientists can all work under one roof, eliminating the need for complex logistics. In December, successfully launched their 3.2 rocket from the Pacific spaceport complex in Kodiak, Alaska, but nearly missed its orbit target. Kemp has said some minor tweaks should resolve the issue and allow them to fly again this summer.

Spacex is currently the dominant maker of large rockets designed to carry thousands of pounds of payload to orbit. But it comes with cost, charging roughly $60 million per launch. By comparison, rocket lab, founded in New Zealand, and now headquartered in the u.s., starts at around $6 million a launch. Astra is now only capable of smaller payloads than both companies, but will charge just $3 million per launch over the next few years.

The first and last rocket company to go public with Orbital Sciences Corporation back in 1990. It since merged into a subsector of Northrop Grumman. Astra will be the only publicly traded company focused solely on building and launching rockets when it begins trading later this year if Kemp can execute his big vision.

As more and more players join the space race, opportunities will become abundant for investors to enter the arena. But questions still remain around when the industry starts making money. Morgan Stanley believes the global space industry could generate more than a trillion in revenue or more in 2040, up from $350 billion right now, over half the growth coming from satellite broadband technology. And as rocket launches get cheaper and more companies look to commercialize space, profitability may soon be taking off.

*Bloomberg contributed to this article

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Sony and TSMC's $6.3 billion image-sensor bet signals a new era of chip co-investment

Sony and TSMC's $6.3 billion image-sensor bet signals a new era of chip co-investment

Sony and TSMC have announced a joint investment of $6.3 billion to develop next-generation image-sensor chips. This collaboration is driven by the increasing demand for AI technologies, which is influencing changes in semiconductor supply chains. The initiative is expected to have significant impacts in 2026.

  • 01Sony and TSMC are investing $6.3 billion in next-generation image-sensor chips.
  • 02The investment is motivated by rising demand for AI technologies.
  • 03The partnership is a notable example of co-investment in the semiconductor industry.

Aug 12, 2026

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512